Abstract
Fifteen patients with proven and evaluable primary advanced lung cancer (small cell carcinoma 1, adeno carcinoma 6, squamous cell carcinoma 6, and large cell carcinoma 2) have been treated with the CMAF therapy since March 1981.
Response was seen in 9 patients (60.0%). There were 6 patients with complete response (40%), and 3 patients with partial response (20%). A good response rate of 66.7% was seen in adenocarcinoma patients. Hematologic toxicity was seen in 10 (43.3%) of 25 patients receiving CMAF, but permanent renal toxicity was not observed. The gastrointestinal toxicity such as nausea and/or vomiting was inhibited in more than 35% of the cases by administering ursodeoxycholic acid concommitantly during therapy.
Therefore, the administration of ursodeoxycholic acid concommitant with chemotherapy may be of practical use to preventing gastrointestinal side-effects of chemotherapy.
